FY2025 · ended Dec 31, 2025 · Revenue $301,647, +78.8% YoY · Filed Mar 25, 2026
Nexalin Technology, Inc. (NXL) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $301,647 and a net loss of $8.2 million.
Revenue (TTM)
$217,155
+24.2% vs year-ago TTM
Net income (TTM)
$-8.99M
-1.6% vs year-ago TTM
Operating cash flow (TTM)
$-6.13M
-43.3% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.46
+33.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
20.58M
+16.6% vs prior year
Net cash
$2.94M
FY 2023
Operating margin
-4202.5%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- NXL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1527352
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $301,647 | $168,721 | $110,748 | $1.3M |
| Operating income | -$8.4M | -$7.8M | -$5.7M | -$1.8M |
| Net income | -$8.2M | -$7.6M | -$4.6M | -$1.7M |
| Diluted EPS | -$0.50 | -$0.83 | -$0.63 | — |
| Operating cash flow | -$5.0M | -$3.9M | -$3.8M | -$2.2M |
| Total assets | $4.6M | $4.2M | $3.6M | $7.4M |
| Total liabilities | $887,333 | $546,694 | $425,281 | $2.0M |
| Stockholders' equity | $3.7M | $3.7M | $3.2M | $5.5M |
| Cash and investments | $3.7M | $3.5M | $2.9M | $7.0M |
| Total debt | — | — | $4,463 | $55,260 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 1, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 27, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Aug 21, 2026 | Aug 21, 2026 |
All 204 Nexalin Technology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.